Susquehanna International Group’s Alzamend Neuro ALZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-27
Closed -$15.6K 11983
2023
Q1
$15.6K Hold
27
﹤0.01% 12109
2022
Q4
$20.3K Buy
27
+12
+80% +$17.4K ﹤0.01% 11761
2022
Q3
$25K Buy
15
+8
+114% +$11K ﹤0.01% 12517
2022
Q2
$9K Sell
7
-11
-61% -$14.3K ﹤0.01% 12523
2022
Q1
$30K Sell
18
-70
-80% -$131K ﹤0.01% 12500
2021
Q4
$225K Sell
88
-19
-18% -$58.8K ﹤0.01% 11194
2021
Q3
$443K Buy
+107
New +$588K ﹤0.01% 9688

Other funds holding ALZN

Susquehanna International Group's ALZN Position: Q4 2024 in Review

Susquehanna International Group sold out of Alzamend Neuro (ALZN) in Q4 2024, closing a stake of 1,845 shares — an estimated $28.1K sold.

Susquehanna International Group first reported a position in ALZN in Q2 2021 and held it in 8 quarters. The position peaked at $498K in Q2 2021. 14 funds tracked by Wall St. Rank hold ALZN as of Q4 2024.

  • Susquehanna International Group reported no remaining Alzamend Neuro position as of Q4 2024 after selling out during the quarter.
  • Susquehanna International Group sold 1,845 Alzamend Neuro shares in Q4 2024, an estimated $28.1K.
  • Susquehanna International Group first reported a position in Alzamend Neuro in Q2 2021 and held it in 8 quarters.
  • Susquehanna International Group's Alzamend Neuro position peaked at $498K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2024.

Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.